Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment and is standard of care in treatment monitoring and decision...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Gökbuget, Nicola, Kantarjian, Hagop M., Brüggemann, Monika, Stein, Anthony S., Bargou, Ralf C., Dombret, Hervé, Fielding, Adele K., Heffner, Leonard, Rigal-Huguet, Françoise, Litzow, Mark, O’Brien, Susan, Zugmaier, Gerhard, Gao, Shan, Nagorsen, Dirk, Forman, Stephen J., Topp, Max S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849936/
https://ncbi.nlm.nih.gov/pubmed/31648325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000457
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge